A recent study conducted by Di Cosimo et al. (2020) used high-throughput analysis of 752 miRNA assays from HER2-positive breast cancer patients to identify differentially expressed ci-miRNAs before and after two weeks of trastuzumab administration [115]. The gene discussed is ERBB2; the disease is breast carcinoma.